GlassScriptPhysician profile
Bari M Byrd
NPI 1114245446
$1,546.33
in general payments reported to CMS, 2019-2025
20 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.31 · 2021: $33.40 · 2022: $220 · 2023: $517 · 2024: $386 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $237.06 | 2022-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $196.58 | 2021-2024 | Myosure Tissue Removal Device, Acessa Provu System, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $184.47 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $158.47 | 2022-2025 | |
| Pfizer INC. | $154.92 | 2019-2025 | |
| Coopersurgical, INC. | $124.84 | 2023-2024 | Endosee, Paragard T 380a, Paragard T 380a |
| Organon LLC | $90.87 | 2023-2025 | Nexplanon |
| Evofem Biosciences, INC. | $86.84 | 2022-2025 | Phexxi, Solosec, Phexx |
| Biogen, INC. | $78.72 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $54.52 | 2023-2025 | Slynd |
| Abbvie INC. | $45.67 | 2022-2023 | Lo Loestrin Fe, Orilissa |
| Bausch Health US, LLC | $23.41 | 2025 | Aplenzin, Wellbutrin |
| Shield Therapeutics INC | $18.79 | 2023 | Accrufer |
| Agile Therapeutics, INC. | $18.68 | 2023 | Twirla |
| Duchesnay USA Incorporated | $18.62 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $14.17 | 2023 | Surgicel Nu-Knit, Enseal, Harmonic |
| Sumitomo Pharma America, INC. | $14.11 | 2023 | Gemtesa |
| Aspira Women'S Health INC | $13.74 | 2024 | Ova1 |
| Therapeuticsmd, INC. | $11.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bari Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.